Blueprint-Medicines-ASCO-2023-BLU-945-EGFRmNSCLC-Monotherapy-Combination-Osimertinib-Short-Oral
Loading viewer...
presentation
Format: PDF presentation
Blueprint-Medicines-ASCO-2023-BLU-945-EGFRmNSCLC-Monotherapy-Combination-Osimertinib-Short-Oral by Blueprint Medicines Corporation.
